Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PAH Clear all
Completed Phase 4 Interventional Results available

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Not applicable Interventional

Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)

NCT03288025
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Insulin Resistance
Interventions
Nutrition and Exercise
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet

NCT03802721
View directory record Official record
Conditions
Environmental Exposure
Interventions
[14C]-benzo[a]pyrene, Brussels sprouts before 50 ng dose, DIM supplement before 50 ng dose
Drug
Lead sponsor
Oregon State University
Other
Eligibility
21 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

NCT01725269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers

NCT00814645
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 80 Years
Enrollment
150 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 4 Interventional Results available

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

NCT02885012
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 3 Interventional

PAH Exercise Study

NCT06941441
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Exercise Therapy
Interventions
Home exercise program
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Results available

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

NCT02657356
View directory record Official record
Conditions
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Interventions
Placebo capsules, Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Pulmonary Hypertension Peripheral Limitations

NCT05968859
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Healthy
Interventions
Aerobic Training, Leg Training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting No phase listed Observational

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

NCT07487441
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Withdrawn Phase 2 Interventional

Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

NCT02108743
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension.
Interventions
Albuterol., Normal saline placebo
Drug
Lead sponsor
American Medical Association Foundation
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
LTP001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636
View directory record Official record
Conditions
Exercise-induced Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational

Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension

NCT04787445
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Nutritional and Neurotransmitter Changes in PKU Subjects on BH4

NCT00688844
View directory record Official record
Conditions
Phenylketonuria
Interventions
KuvanTM Therapy
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

NCT00105209
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Aspirin, clopidogrel
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational

Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension

NCT05521113
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Home Rehabilitation Monitoring System, Health coaching calls
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Withdrawn Not applicable Interventional

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

NCT05618093
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions
Non-invasive hemodynamic measurements
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational

Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH

NCT02631421
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Blood Sampling, Cardiac MRI
Procedure · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 22, 2026, 5:25 AM EDT